The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) closed at $4.41 down -6.86% from its previous closing price of $4.74. In other words, the price has decreased by -$6.86 from its previous closing price. On the day, 0.52 million shares were traded. SONN stock price reached its highest trading level at $4.9897 during the session, while it also had its lowest trading level at $4.3301.
Ratios:
For a deeper understanding of Sonnet BioTherapeutics Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SONN now has a Market Capitalization of 30108622 and an Enterprise Value of 29534232. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.11. Its current Enterprise Value per Revenue stands at 29.534 whereas that against EBITDA is -2.102.
Stock Price History:
The Beta on a monthly basis for SONN is 1.39, which has changed by -0.047516227 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, SONN has reached a high of $19.30, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 3.63%, while the 200-Day Moving Average is calculated to be 75.13%.
Shares Statistics:
For the past three months, SONN has traded an average of 1.78M shares per day and 541040 over the past ten days. A total of 6.83M shares are outstanding, with a floating share count of 6.56M. Insiders hold about 3.95% of the company’s shares, while institutions hold 2.64% stake in the company. Shares short for SONN as of 1759190400 were 2154301 with a Short Ratio of 1.21, compared to 1756425600 on 1866078. Therefore, it implies a Short% of Shares Outstanding of 2154301 and a Short% of Float of 31.6.
Earnings Estimates
The market rating of Sonnet BioTherapeutics Holdings Inc (SONN) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.
Analysts are recommending an EPS of between -$3.46 and -$3.46 for the fiscal current year, implying an average EPS of -$3.46.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for SONN’s current fiscal year. The highest revenue estimate was $1M, while the lowest revenue estimate was $1M, resulting in an average revenue estimate of $1M. In the same quarter a year ago, actual revenue was $18.63k
